“Cost-Per-Responder Analysis of Tralokinumab Versus Dupilumab in Patients With Moderate-to-Severe Atopic Dermatitis in the US and Canada”. 2024. SKIN The Journal of Cutaneous Medicine 8 (1): s317. https://doi.org/10.25251/skin.8.supp.317.